Desktop oligosynthesizers: a case study for supporting biotechnology innovation through biosecurity governance, biosafety risk assessment and mitigation strategies

Read full text Summarise with VIRAT
Authors: Ami Patel, Elaine B. Jarvis, Colin Price, Kenny Yeh
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Emerging synthetic biology tools have tremendous potential to revolutionize biotechnology advancement. At the helm of this wave are desktop oligosynthesizers, which are instruments that can quickly generate nucleic acids on-demand potentially without strict third-party oversight. In the biodefense context, this capability can further catalyze innovation in biothreat preparedness and disease surveillance, especially if these platforms become widely adapted. As a result, new biosecurity challenges will arise requiring unique implementation considerations beyond current U.S. policies. Here we present a case study that highlights the use of a desktop oligosynthesizer for a biodefense R&D application. We established new biosafety approvals, biosecurity standards, and quality review processes for Sequence of Concern (SoC) screening to support this effort. Their creation was necessary for translating office-to-lab bench policy based on the 2024 OSTP Framework for Nucleic Acid Synthesis Screening, which the 2025 Executive Order: Improving the Safety and Security of Biological Research may revise in the future. Our experience highlights the importance of multi-stakeholder collaborations to implement effective internal requirements, safeguard critical information, and support biodefense innovation.

Fields of Study & Subjects

Global Security and Public Health Chemical Safety and Risk Management Law AI and Intellectual Property

Publication details

Journal / source
New Prairie Press (Kansas State University)
Publication date
23 March 2026
Language
EN